We are live on
!
Find out more
PP
PDT Partners Portfolio holdings
AUM
$1.69B
1-Year Est. Return
74.01%
This Fund
S&P 500
This Quarter
Est. Return
+3.39%
1 Year Est. Return
+74.01%
3 Year Est. Return
+179.69%
5 Year Est. Return
+210.81%
10 Year Est. Return
+1,321.68%
AUM
$661M
AUM Growth
-$473M
(-42%)
Cap. Flow
-$486M
Cap. Flow
% of AUM
-73.58%
Top 10 Holdings %
Top 10 Hldgs %
6.77%
Holding
1,175
New
248
Increased
83
Reduced
484
Closed
358
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coupang
CPNG
|
+$3.58M |
| 2 |
AutoZone
AZO
|
+$3.03M |
| 3 |
Howmet Aerospace
HWM
|
+$2.87M |
| 4 |
ANSS
Ansys
ANSS
|
+$2.84M |
| 5 |
Gartner
IT
|
+$2.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$7.61M |
| 2 |
General Motors
GM
|
+$6.29M |
| 3 |
Bunge Global
BG
|
+$5.38M |
| 4 |
Qualcomm
QCOM
|
+$5M |
| 5 |
US Foods
USFD
|
+$4.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.14% |
| 2 | Healthcare | 20.5% |
| 3 | Financials | 14.07% |
| 4 | Industrials | 12.62% |
| 5 | Consumer Discretionary | 11.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
651
Dyne Therapeutics
DYN
$4.15B
| $250K | 0.04% |
19,705
-2,918
| -13% | -$33.5K |
|
652
Cannae Holdings
CNNE
$653M
| $249K | 0.04% |
+12,039
| New | +$259K |
|
|
AYX
653
DELISTED
Alteryx Inc
AYX
| $246K | 0.04% |
+4,405
| New | +$258K |
|
|
MAXR
654
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
| $244K | 0.04% |
13,015
-20,736
| -61% | -$509K |
|
655
Repligen
RGEN
$6.91B
| $243K | 0.04% |
+1,300
| New | +$274K |
|
656
Arcutis Biotherapeutics
ARQT
$3.48B
| $242K | 0.04% |
+12,673
| New | +$287K |
|
|
CHS
657
DELISTED
Chicos FAS, Inc.
CHS
| $242K | 0.04% |
+49,898
| New | +$277K |
|
658
Monarch Casino & Resort
MCRI
$2.2B
| $241K | 0.04% |
4,297
-11,235
| -72% | -$688K |
|
659
Intapp
INTA
$2.44B
| $240K | 0.04% |
12,867
+2,278
| +22% | +$35.8K |
|
660
Designer Brands
DBI
$315M
| $238K | 0.04% |
15,531
-41,615
| -73% | -$652K |
|
661
Exponent
EXPO
$3.19B
| $237K | 0.04% |
+2,703
| New | +$256K |
|
662
Halozyme
HALO
$9.88B
| $237K | 0.04% |
+6,000
| New | +$265K |
|
663
Imperial Oil
IMO
$62.3B
| $237K | 0.04% |
+5,471
| New | +$250K |
|
664
Simply Good Foods
SMPL
$907M
| $237K | 0.04% |
+7,407
| New | +$243K |
|
|
TVRD
665
Tvardi Therapeutics
TVRD
$20.1M
| $236K | 0.04% |
702
-426
| -38% | -$154K |
|
666
Landstar System
LSTR
$6.03B
| $235K | 0.04% |
+1,629
| New | +$243K |
|
667
Regenxbio
RGNX
$616M
| $235K | 0.04% |
8,906
-6,479
| -42% | -$192K |
|
|
TRTN
668
DELISTED
Triton International Limited
TRTN
| $235K | 0.04% |
+4,293
| New | +$257K |
|
669
Edgewise Therapeutics
EWTX
$4.28B
| $233K | 0.04% |
+23,657
| New | +$239K |
|
670
Trade Desk
TTD
$8.97B
| $233K | 0.04% |
+3,900
| New | +$222K |
|
671
Cisco
CSCO
$443B
| $232K | 0.04% |
+5,800
| New | +$257K |
|
|
GES
672
DELISTED
Guess Inc
GES
| $232K | 0.04% |
+15,815
| New | +$283K |
|
673
Intuit
INTU
$91.1B
| $232K | 0.04% |
600
-4,716
| -89% | -$2.04M |
|
|
PRVB
674
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $232K | 0.04% |
51,594
-41,415
| -45% | -$189K |
|
|
DCH
675
Dauch Corp
DCH
$1.31B
| $229K | 0.03% |
+33,513
| New | +$302K |
|
Similar funds
ISS
GAM
BCM
FACM
TCBWMS
SGI
AAM
RSCM
PDT Partners's Q3 2022 Portfolio in Review
As of Q3 2022, PDT Partners held 1,175 positions worth $661M, down 42% from $1.13B the previous quarter. Its ten largest holdings account for 6.8% of the portfolio.
PDT Partners withdrew a net $486M in Q3 2022, closing 358 positions and reducing 484 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $7.61M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 21% a quarter earlier, followed by Healthcare and Financials.
Against the trend, PDT Partners opened a new position in Coupang worth $3.45M.
- PDT Partners's largest Q3 2022 buy was Coupang: 207,142 shares worth $3.45M.
- PDT Partners added most to AutoZone in Q3 2022, an estimated $3.03M increase.
- PDT Partners's biggest Q3 2022 reduction was General Motors, cutting an estimated $6.29M.
- PDT Partners fully exited Vertex Pharmaceuticals in Q3 2022, selling an estimated $7.61M.
- PDT Partners's ten largest holdings make up 6.8% of its $661M portfolio in Q3 2022.
- PDT Partners opened 248 new positions and closed 358 in Q3 2022.
- PDT Partners's portfolio value fell 42% quarter-over-quarter to $661M.
Based on PDT Partners's 13F filing for Q3 2022, filed 14 Nov 2022.